JAN (NYSE:JAN – Get Free Report) was upgraded by investment analysts at Compass Point to a “hold” rating in a research report issued on Wednesday, Zacks reports.
Other equities analysts have also recently issued reports about the company. Morgan Stanley raised their price objective on JAN from $28.00 to $31.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 18th. Barclays increased their target price on shares of JAN from $33.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, August 31st. Wells Fargo & Company lifted their price target on shares of JAN from $33.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, September 1st. Raymond James Financial began coverage on shares of JAN in a research report on Tuesday, June 16th. They set a “strong-buy” rating and a $34.00 price objective for the company. Finally, Zacks Research downgraded JAN from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, JAN presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.31.
View Our Latest Stock Analysis on JAN
JAN Price Performance
JAN (NYSE:JAN – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The business had revenue of $216.46 million during the quarter, compared to the consensus estimate of $203.32 million. The business’s quarterly revenue was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. On average, analysts predict that JAN will post 0.97 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Greenland Capital Management LP acquired a new stake in shares of JAN in the second quarter valued at approximately $575,000. Readystate Asset Management LP acquired a new position in shares of JAN during the second quarter worth approximately $1,724,000. WINTON GROUP Ltd bought a new position in JAN in the 2nd quarter worth approximately $2,985,000. Wellington Management Group LLP acquired a new stake in JAN in the 2nd quarter valued at approximately $8,739,000. Finally, Engineers Gate Manager LP bought a new stake in JAN during the 2nd quarter valued at $15,274,000. 6.27% of the stock is owned by institutional investors and hedge funds.
Trending Headlines about JAN
Here are the key news stories impacting JAN this week:
- Positive Sentiment: Monthly dividend provides income support: JAN declared a monthly dividend of $0.0475 per share, equivalent to an annualized yield of approximately 1.8%. The upcoming payments are scheduled for October 28, November 23, and December 29, 2026. JAN dividend announcement
- Positive Sentiment: Revenue growth remains strong: JAN reported quarterly revenue of $216.46 million, up 45.4% year over year and above the $203.32 million analyst consensus. Full-year fiscal 2026 guidance calls for earnings per share of $0.95 to $0.98.
- Neutral Sentiment: Analyst target indicates limited near-term upside: Analysts assign JAN an average price target of $31.71, modestly above the recent trading level. This suggests some potential upside, but not a major revaluation catalyst. JAN receives average analyst price target
- Negative Sentiment: Latest earnings missed expectations: JAN reported earnings of $0.05 per share, falling short of the $0.23 consensus estimate by $0.18. The earnings miss is likely the most important pressure on the stock, despite the better-than-expected revenue and continued growth.
- Negative Sentiment: Upside is being weighed against execution risk: With shares trading near the 50-day moving average and the analyst target only modestly higher, investors may remain cautious until JAN demonstrates that it can convert its revenue growth into stronger profitability.
JAN Company Profile
JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company’s activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.
JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.
The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.
Featured Stories
- Five stocks we like better than JAN
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
Receive News & Ratings for JAN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JAN and related companies with MarketBeat.com's FREE daily email newsletter.
